Turk Ilac ve Serum Sanayi AS (IS:TRILC) — Stock Price
Turk Ilac ve Serum Sanayi AS (IS:TRILC) is currently trading at TL1.19 TRY, down 0.83% today. Over the past 52 weeks, shares have ranged between TL1.13 and TL25.26. This page tracks Turk Ilac ve Serum Sanayi AS's live share price on the IS exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see TRILC stock market capitalisation.
Turk Ilac ve Serum Sanayi AS (TRILC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Turk Ilac ve Serum Sanayi AS's daily closing share price and trading volume on the IS exchange over the past year, giving a clear view of recent price momentum and liquidity.
Turk Ilac ve Serum Sanayi AS Income Statement — Revenue, Profit & Earnings by Year
Turk Ilac ve Serum Sanayi AS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | TL2.57 Billion | TL2.77 Billion | TL833.44 Million | TL672.60 Million | TL199.50 Million |
| Cost of Revenue | TL1.77 Billion | TL2.14 Billion | TL625.34 Million | TL552.24 Million | TL100.41 Million |
| Gross Profit | TL801.53 Million | TL631.49 Million | TL208.10 Million | TL120.37 Million | TL99.09 Million |
| Research & Development | — | — | — | — | — |
| SG&A | TL173.02 Million | TL160.57 Million | TL49.31 Million | TL16.48 Million | TL10.21 Million |
| Total Operating Expenses | TL2.03 Billion | TL2.37 Billion | TL761.63 Million | TL596.99 Million | TL127.95 Million |
| Operating Income | TL542.03 Million | TL403.87 Million | TL71.81 Million | TL75.61 Million | TL71.55 Million |
| EBITDA | — | — | TL174.53 Million | TL86.67 Million | TL88.82 Million |
| EBIT | — | — | TL69.98 Million | TL73.08 Million | TL70.17 Million |
| Interest Expense | TL668.08 Million | TL251.15 Million | TL83.96 Million | TL32.09 Million | TL41.86 Million |
| Income Before Tax | TL98.38 Million | TL118.56 Million | TL80.30 Million | TL46.86 Million | TL40.26 Million |
| Income Tax Expense | — | — | TL13.92 Million | TL9.72 Million | TL6.93 Million |
| Net Income | TL72.36 Million | TL152.63 Million | TL66.38 Million | TL37.14 Million | TL33.33 Million |
Turk Ilac ve Serum Sanayi AS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Turk Ilac ve Serum Sanayi AS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | TL3.99 Billion | TL2.82 Billion | TL1.04 Billion | TL619.53 Million | TL399.12 Million |
| Total Current Assets | TL2.08 Billion | TL1.23 Billion | TL535.74 Million | TL380.91 Million | TL223.15 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | TL19.65K | — | — |
| Net Receivables | TL1.21 Billion | TL1.07 Billion | TL390.90 Million | TL262.26 Million | TL143.53 Million |
| Inventory | TL431.63 Million | TL64.94 Million | TL46.65 Million | TL42.62 Million | TL47.46 Million |
| Property, Plant & Equipment | — | — | TL415.73 Million | TL237.76 Million | TL175.10 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | TL2.07 Billion | TL1.04 Billion | TL479.65 Million | TL295.46 Million | TL250.99 Million |
| Total Current Liabilities | TL1.07 Billion | TL969.47 Million | TL411.83 Million | TL259.28 Million | TL210.05 Million |
| Long-term Debt | TL914.81 Million | TL23.96 Million | TL12.54 Million | TL12.42 Million | TL19.24 Million |
| Net Debt | TL1.64 Billion | TL579.48 Million | TL262.67 Million | TL148.57 Million | TL118.09 Million |
| Total Stockholder Equity | TL1.92 Billion | TL1.78 Billion | TL564.69 Million | TL324.08 Million | TL148.13 Million |
| Retained Earnings | TL621.05 Million | TL548.69 Million | TL135.18 Million | TL68.80 Million | TL31.66 Million |
Turk Ilac ve Serum Sanayi AS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Turk Ilac ve Serum Sanayi AS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | TL-378.48 Million | TL408.19 Million | TL-11.88 Million | TL-71.67 Million | TL33.20 Million |
| Capital Expenditures | TL151.66 Million | TL115.31 Million | TL38.42 Million | TL20.60 Million | TL16.54 Million |
| Free Cash Flow | TL-530.14 Million | TL292.88 Million | TL-50.30 Million | TL-92.33 Million | TL16.25 Million |
| Investing Cash Flow | — | — | TL-38.41 Million | TL-19.83 Million | TL-14.60 Million |
| Financing Cash Flow | — | — | TL42.33 Million | TL135.88 Million | TL-19.73 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | TL8.53 Million | TL39.83 Million | TL10.27 Million | TL7.73 Million | TL6.69 Million |
| Change in Cash | TL-1.16 Million | TL-79.08 Million | TL-7.96 Million | TL44.38 Million | TL-1.13 Million |
Turk Ilac ve Serum Sanayi AS Earnings History — EPS Actual vs. Analyst Estimates
Track Turk Ilac ve Serum Sanayi AS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 0.20 | — | — |
| Dec 31, 2025 | -0.12 | — | — |
| Sep 30, 2025 | 0.11 | — | — |
| Jun 30, 2025 | -0.24 | — | — |
| Mar 31, 2025 | -0.29 | — | — |
| Dec 31, 2024 | 0.00 | — | — |
| Sep 30, 2024 | 0.00 | — | — |
| Jun 30, 2024 | 0.09 | — | — |